The FDA has approved specific GLP-1 formulations for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
* Only applies to purchases made directly through our website.
This is because the weekly injection requires a higher dose, which may lead to more pronounced side effects compared to the daily injection
Within the study population of women with type 2 diabetes, 5.58% of infants were born with an MCM and 2.25% were born with a cardiac malformation, compared to 3.76% and 1.31%, respectively, of infants born to the general population
If you miss a dose, follow your medication instructions or message your provider for guidance
The Major Market Leaders Operating in the Market Are: Novo Nordisk A/S (Denmark) Lilly (U.S.) Sanofi (France) AstraZeneca (U.K.) Pfizer Inc